Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Sheila Annie Peters

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations - Sheila Annie Peters


Скачать книгу
G., Váradi, A., Özvegy‐Laczka, C. et al. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME‐Tox). Drug Discov Today https://doi.org/10.1016/j.drudis.2007.12.010.

      32 Uchimura, T., Kato, M., Saito, T. et al. (2010). Prediction of human blood‐to‐plasma drug concentration ratio. Biopharm Drug Dispos 31 (5–6): 286–297. https://doi.org/10.1002/bdd.711.

      33 Varma, M.V.S. et al. (2009). Physicochemical determinants of human renal clearance. J Med Chem 52 (15): 4844–4852. https://doi.org/10.1021/jm900403j.

      34 Van De Water, F.M., Masereeuw, R., and Russel, F.G.M. (2005). Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab Rev 37 (3): 443–471. https://doi.org/10.1080/03602530500205275.

      35 Wright, J.D., Boudinot, F.D., and Ujhelyi, M.R. (1996). Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30 (6): 445–462. https://doi.org/10.2165/00003088‐199630060‐00003.

      36 Wright, S.H. and Dantzler, W.H. (2004). Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84 (3): 987–1049. https://doi.org/10.1152/physrev.00040.2003.

      37 Zhang, E.Y., Knipp, G.T., Ekins, S. et al. (2002). Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev 34 (4): 709–750. https://doi.org/10.1081/DMR‐120015692.

      CONTENTS

      1  2.1 Introduction

      2  2.2 Drug Interactions Mediated by Enzymes and Transporters at Various Sites

      3  2.3 Factors Affecting DDI

      4  2.4 In Vitro Methods to Evaluate Drug–Drug Interactions 2.4.1 Candidate Drug as a Potential Perpetrator 2.4.2 Candidate Drug as a Potential Victim of Inhibition

      5  2.5 Sources of Uncertainty

      6  2.6 Therapeutic Protein–Drug Interaction Keywords References

Schematic illustration of potential sources of DDI risks for a new molecular entity.
DDI mechanisms Liver Intestine Kidney Blood–brain barrier

Скачать книгу
Librs.Net